Panacea Biotec Limited has informed the Exchange about General Updates
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Panacea Biotec, along with ICMR, has completed enrollment of 10,335 study participants for the Phase III clinical trial of DengiAll®, its tetravalent dengue candidate vaccine. This follows the trial initiation announced in August 2024. Each participant will now be monitored for two years to assess the vaccine's efficacy and immunogenicity. DengiAll® is positioned as India's first indigenous single-shot dengue vaccine and is expected to reach the market by 2027.
This is a positive development but commercial revenue is still 1-2 years away given the two-year monitoring period and expected 2027 launch. Shareholders should view this as a meaningful clinical milestone that de-risks the development pipeline, though no immediate financial impact is expected.